Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation

Hiroyuki Osanai; Masayoshi Ajioka; Tomohiro Masutomi; Tasuku Kuwayama; Sota Ishihama; Maki Takahashi; Takahiro Kanbara; Yosuke Inoue; Yoshihito Nakashima; Hiroshi Asano; Kazuyoshi Sakai

doi:10.1253/circj.CJ-15-1281

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation

Hiroyuki Osanai, Masayoshi Ajioka, Tomohiro Masutomi, Tasuku Kuwayama, Sota Ishihama, Maki Takahashi, Takahiro Kanbara, Yosuke Inoue, Yoshihito Nakashima, Hiroshi Asano, Kazuyoshi Sakai

著者情報

キーワード: Anti-factor Xa activity, Atrial fibrillation, Edoxaban

ジャーナルフリー HTML 早期公開

論文ID: CJ-15-1281

DOI https://doi.org/10.1253/circj.CJ-15-1281

この記事には本公開記事があります。

The final version of this article is now available: Vol. 80 (2016), No. 3 pp. 745-747

詳細

抄録

Background:The distribution of anti-factor Xa activity (AXA) values in non-valvular atrial fibrillation (NVAF) patients on edoxaban therapy has not been fully elucidated.Methods and Results:The steady-state trough and peak AXA values were measured in 66 NVAF patients. The trough AXA value did not differ significantly between the 60-mg and the 30-mg OD groups (0.17±0.13 IU/ml vs. 0.12±0.11 IU/ml, respectively; P=0.17). Similarly, the peak AXA value did not differ significantly between the 2 groups (1.45±0.81 IU/ml vs. 1.25±0.48 IU/ml, respectively; P=0.26).Conclusions:Recommended dosing should be followed for sufficient efficacy of edoxaban.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）